Search

Your search keyword '"Chiang, Chern"' showing total 1,090 results

Search Constraints

Start Over You searched for: Author "Chiang, Chern" Remove constraint Author: "Chiang, Chern"
1,090 results on '"Chiang, Chern"'

Search Results

1. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

5. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial

7. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome

8. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

9. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

10. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

14. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

15. Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients

16. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial

20. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

22. Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure

23. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

24. 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

25. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

29. Effects of Dapagliflozin in Patients in Asia:A Post Hoc Subgroup Analysis From the DELIVER Trial

30. Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction.

31. Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials.

33. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

37. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients

38. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

39. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial

40. Efficacy and Safety of Inclisiran in Asian Patients

44. 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases

46. Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015

49. CARDIOVASCULAR RISK IN TREATED HYPERTENSIVE PATIENTS WITH ISOLATED DIASTOLIC HYPERTENSION AND ISOLATED LOW DIASTOLIC BLOOD PRESSURE

Catalog

Books, media, physical & digital resources